PPH ETF Analysis: Pharmaceutical | NASDAQ
Health | NASDAQ, USA | Market Cap: 917m USD | 12M Return: 36.2% | US92189F6925 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.5M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The VanEck Pharmaceutical ETF (PPH) is a non-diversified fund that invests at least 80% of its total assets in securities matching its benchmark index. The index tracks common stocks and depositary receipts of U.S. exchange-listed pharmaceutical companies, including medium-capitalization firms and foreign companies listed on U.S. exchanges.
The pharmaceutical sector includes companies engaged in the research, development, manufacturing, and commercialization of drugs and therapies. As a sector-specific, non-diversified ETF, PPH concentrates its holdings within a single industry, exposing investors to the performance and risks associated with pharmaceutical companies rather than spreading investments across multiple sectors.
- Medicare drug price negotiations pressure sector revenue and margins
- Patent expirations expose top holdings to generic competition
- FDA pipeline approvals drive pharmaceutical revenue growth
As of August 14, 2026, the stock is trading at USD 111.43 with a total of 153,842 shares traded. Over the past week, the price has changed by +1.42%, over one month by +2.44%, over three months by +10.77% and over the past year by +36.21%.
Current recommended Stop Loss: 108.90 (which is 2.3% or 1.2 ATR below the current price).
Pharmaceutical has no consensus analysts rating.